Enzo

The Enzo shareholder issued an open letter stating its concern about the company's stock performance.

Enzo's fiscal first quarter revenues grew 2 percent year over year to $25.2 million, driven by an 8 percent spike in clinical laboratory services.

It's the first approved test to feature the firm's proprietary AmpiProbe nucleic acid amplification and detection platform.

Affymetrix will pay Enzo $10 million to settle litigation Enzo brought against the company over a method for nucleic acid analysis.

As part of a settlement deal, Siemens will pay Enzo an upfront fee of $9.5 million and potentially up to $5 million in licensing royalties.

The US District Court in Delaware has adopted Enzo's interpretation of patent language and rejected the defendants' argument to invalidate a key patent.

Luminex will pay Enzo Biochem $7.1 million to settle a lawsuit alleging infringement of patents for oligonucleotides and solid supports for fixed nucleic acids.

An 8 percent increase in Enzo Clinical Lab revenues was offset by a 9 percent decrease in Life Sciences revenues.

Hologic said in its Form 10-Q that Enzo sued the firm in March alleging infringement of a patent related to labeled nucleotides for use as diagnostic tools.

The appeals court reversed in part an earlier decision by aUSdistrict court that resulted in a $61 million award to Enzo, and remanded the case back to the district court.